Kaoru Tsuchiya, Yasuhiro Asahina, Shuya Matsuda, Masaru Muraoka, Toru Nakata, Yuichiro Suzuki, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Takanori Hosokawa, Takashi Nishimura, Ken Ueda, Teiji Kuzuya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Masayuki Kurosaki, Nobuyuki Enomoto and Namiki Izumi Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma Cancer 120
Version of Record online: 7 OCT 2013 | DOI: 10.1002/cncr.28384
Vascular endothelial growth factor (VEGF) is one of the most important targets of sorafenib. Serial changes in plasma VEGF concentrations during sorafenib treatment are dynamic, and a decrease in plasma VEGF 8 weeks after starting sorafenib is a useful predictor of favorable overall survival in patients with advanced hepatocellular carcinoma.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field